<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen126">
		<pathogen_name>Dengue Virus</pathogen_name>
		<taxon_id>12637</taxon_id>
		<pathogenesis refs="reference1550">During the feeding of mosquitoes on humans, DENV is presumably injected into the bloodstream, with spillover in the epidermis and dermis, resulting in infection of immature Langerhans cells (epidermal dendritic cells [DC]), and keratinocytes. Infected cells then migrate from site of infection to lymph nodes, where monocytes and macrophages are recruited, which become targets of infection. Consequently, infection is amplified and virus is disseminated through the lymphatic system. As a result of this primary viremia, several cells of the mononuclear lineage, including blood-derived monocytes, myeloid DC, and splenic and liver macrophages are infected (Martina et al., 2009).</pathogenesis>
		<disease_name>Dengue Fever</disease_name>
		<protective_immunity refs="reference1550">In most acute virus infection models, the presence of antibodies, both neutralizing and nonneutralizing, correlates with control, elimination, and eventually protection (Martina et al., 2009).</protective_immunity>
		<host_range refs="reference1550">Dengue is transmitted to humans by Aedes mosquitoes, mainly Aedes aegypti. There is no animal model of disease that mimics the disease in humans (Martina et al., 2009).</host_range>
		<introduction refs="reference1373">Dengue (DEN) viruses belong to the family Flaviviridae and consist of four distinct antigenic serotypes, DEN1â€“4. DEN viruses are transmitted primarily by the mosquito Aedes aegypti and cause over 100 million human infections per year, which are manifested clinically by either DEN fever (DF), a self-limited febrile illness, or more severe DEN hemorrhagic fever/DEN shock syndrome (DHF/DSS) usually with a mortality that ranges from 1 to 5%. Epidemic DF/DHF has been emerging as one of the most important global public health problems in the tropical and subtropical countries at the beginning of the 21st century. It is imperative to support research on the development of new mosquito control technology and on the establishment of preventive strategies, including the development of effective and safe dengue vaccines (Liu et al., 2006).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine4115">
		<vaccine_name>CAdVax-Den12/Den34</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004643</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3100">using a complex adenovirus vector, by incorporating the genes expressing premembrane (prM) and envelope (E) proteins of dengue virus types 1 and 2 (dengue-1 and -2, respectively) (CAdVax-Den12) or dengue-3 and -4 (CAdVax-Den34) (Raviprakash et al., 2008).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1754" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3100">Rhesus macaques were vaccinated by intramuscular inoculation of a tetravalent dengue vaccine formulated by combining the two bivalent vaccine constructs (Raviprakash et al., 2008).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3100">For both of these virus challenge studies, significant protection from viremia was demonstrated for all four dengue virus serotypes in vaccinated animals. Viremia from dengue-1 and dengue-3 challenges was completely blocked, whereas viremia from dengue-2 and dengue-4 was significantly reduced, as well as delayed, compared to that of control-vaccinated animals (Raviprakash et al., 2008).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3100">The ability of the vaccine to induce rapid, as well as sustained, protective immune responses was examined with two separate live-virus challenges administered at 4 and 24 weeks after the final vaccination (Raviprakash et al., 2008).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine855">
		<vaccine_name>Dengue DNA Vaccine encoding NS1 Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011454</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref1374:Wu et al., 2003]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering325" gene_id="gene781">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response613" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57/BL6, Balb/c, and C3H</host_strain>
			<vaccination_protocol refs="reference1374">Groups of 3â€“4 weeks old female C3H mice were initially immunized with 80 Î¼g of recombinant DNA pD2NS1, or pcDNA3 as a control. Recombinant pD2NS1 in PBS, control pcDNA3 in PBS, or PBS buffer alone was intramuscularly (i.m.) injected into the mouse thighs; the mice were subsequently boosted twice using the same method at 1 week interval (Wu et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1374">Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival (Wu et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1374">One week after the final boost, mice were i.v. challenged with 5Ã—10^6 plaque-forming units of PL046 in 100 Î¼l PBS. The mice after virus challenge were monitored daily for morbidity and mortality for weeks (Wu et al., 2003).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine858">
		<vaccine_name>Dengue Subunit E Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011457</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector>Baculovirus [Ref1371:Delenda et al., 1994]</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering329" gene_id="gene780">
			<type>Recombinant protein preparation</type>
			<description refs="reference1371">Baculovirus was used to generate the recombinant protein (Delenda et al., 1994).</description>
		</gene_engineering>
		<host_response host_response_id="host_response616" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="">Three-week-old female BALB/c mice were immunized by intraperitoneal injection on days 1,7, 21 and 56 with 200 gl of baculovirus infected Sf9 cell lysates (CL) or concentrated supernatant fluids (SF) supplemented with complete Freund adjuvant for the first and with incomplete Freund adjuvant for the three other injections.</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1371">Sixty eight percent (P &lt; 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge (Delenda et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1371">Mice were challenged withDEN-2 virus (Delenda et al., 1994).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine856">
		<vaccine_name>Dengue Vaccine using Vaccinia Virus expressing M Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011455</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia virus [Ref1376:Bray and Lai, 1991].</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering327" gene_id="gene785">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response615" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1376">BALB/c mice were immunized by i .p .inoculation of 107 p .f .u . of recombinant vaccinia virus expressing M protein (Bray and Lai, 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1376">Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1376">The mice were challenged at age 6 weeks by intracardiac (i.c.) challenge of 100 LD50 of D4 virus, then observed 21 days for signs of encephalitis or death (Bray and Lai, 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine853">
		<vaccine_name>Dengue Vaccine using Vaccinia Virus expressing prM Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011452</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Vaccinia virus [Ref1376:Bray and Lai, 1991].</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering324" gene_id="gene784">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response612" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1376">BALB/c mice were immunized by i .p .inoculation of 10^7 p .f .u . of recombinant vaccinia virus (Bray and Lai, 1991).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1376">Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge (Bray and Lai, 1991).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1376">The mice were challenged at age 6 weeks by i .c challenge of 100 LD50 of D4 virus, then observed 21 days for signs of encephalitis or death (Bray and Lai, 1991).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3783">
		<vaccine_name>Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004473</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVR1040(Vical Inc.) [Ref2410:Raviprakash et al., 2001]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2410">GM-CSF (Raviprakash et al., 2001)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2410">E, prM, and LAMP from dengue virus 2 New Guinea C (Raviprakash et al., 2001)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1524" gene_id="gene1378">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1525" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1486" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2410">When injected into mice, D2MEL elicited an enhanced antibody response compared to D2ME, which was further augmented by coimmunization with a plasmid expressing mouse granulocyte-monocyte colony stimulating factor (GM-CSF).  Neutralizing antibodies are thought to be of paramount importance for protection against dengue disease (Raviprakash et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3778">
		<vaccine_name>Dengue virus DNA vaccine D1ME encoding prM and E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004470</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVR1012 (Vical Inc.) [Ref2407:Raviprakash et al., 2000]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1311" gene_id="gene1381">
			<type>DNA vaccine construction</type>
			<description refs="reference2407">Vector pVR1012 expressed the dengue-1 pre-membrane (prM) and full-length envelope (E) genes (Raviprakash et al., 2000).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1312" gene_id="gene1380">
			<type>DNA vaccine construction</type>
			<description refs="reference2407">Vector pVR1012 (Vical Inc.) expressed the dengue-1 pre-membrane (prM) and full-length envelope (E) genes (Raviprakash et al., 2000).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1208" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2407">Four of the eight i.m.-inoculated monkeys were protected completely from developing viraemia when challenged 4 months after the last dose with homologous dengue virus. The other four monkeys had reduced viraemia compared with the control immunized monkeys. The i.d. -inoculated monkeys showed no reduction in viraemia when challenged with the virus (Raviprakash et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3903">
		<vaccine_name>Dengue Virus DNA Vaccine D1ME-VRP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004548</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>D1ME-DNA [Ref2668:Chen et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1452" gene_id="gene1380">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1453" gene_id="gene1381">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1544" host_id="host55">
			<immune_response refs="reference2668">After the third dose of vaccine, all animals in the DDD group, VVV group, and DDV group had developed neutralizing antibodies. The dengue virus 1-specific IgG response to all vaccination regimens was predominantly of the IgG1 type, with smaller amounts of IgG2 and no measurable amounts of IgG4 (Chen et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2668">Monkeys were divided into groups DDD, VVV, DDV, and control and immunized with D1ME-DNA or D1ME-VRP as shown in the study design. D1ME-DNA was administered intramuscularly, with 0.5 ml given in each of the two upper arms. D1ME-VRP was delivered intramuscularly, as well (Chen et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2668">All vaccination regimens showed significant protection from viremia compared to that of the unvaccinated control group (Chen et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2668">Twenty weeks after the final immunization, animals were challenged by subcutaneous injection of 10^5 PFU of live dengue virus 1 (Western Pacific 74 strain) in a 0.5-ml volume (Chen et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3904">
		<vaccine_name>Dengue Virus DNA Vaccine encoding NS1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004549</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcTPANS1 [Ref2409:Costa et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2409">NS1 from dengue virus 2 strain NGC (Costa et al., 2006)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1454" gene_id="gene781">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1545" host_id="host3">
			<immune_response refs="reference2409">All Balb/c mice intramuscularly inoculated with the pcTPANS1 presented high levels of NS1-specifc antibodies (Costa et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2409">Male Balb/c mice, 4â€“6 weeks old, were intramuscularly injected in each hind limb tibialis anterior muscle with 50 Î¼g of the pcTPANS1 or pcDNA3 plasmids dissolved in 50 Î¼l of PBS (100 Î¼g/dose/mice). Mice were inoculated with two DNA doses, given two weeks apart, and bled before immunization and 4 weeks after the first DNA dose (Costa et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2409">Vaccinated animals were challenged with intracerebral DENV-2 virus inoculations and a 100% survival was observed (Costa et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2409">Two weeks after the second DNA dose, each immunized mouse was challenged with intracerebral inoculation with 30 Î¼L of 4.32 log10 PFU of DENV2 (Costa et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3902">
		<vaccine_name>Dengue Virus DNA Vaccine expressing prM/E proteins</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004547</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>DENV-4-DNAv [Ref2667:Lima et al., 2011]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2667">prM and E proteins from dengue virus 4 strain H241 (Lima et al., 2011)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1450" gene_id="gene784">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1451" gene_id="gene1383">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1543" host_id="host3">
			<immune_response refs="reference2667">The animals immunized with DENV-4-DNAv produced rising levels, after each vaccine inoculation, of specific neutralizing antibodies against dengue-4 virus (Lima et al., 2011).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2667">Ten 5-week-old female BALB/c mice per immunization group were inoculated three times into the quadriceps muscle with 100 Î¼g of DENV-4-DNAv or pCI (empty vector), DENV-4 heat inactivated (1 Ã— 10^5 PFU), or PBS. The mice were primed on day 0 and boosted 15 and 30 days after the initial inoculation (Lima et al., 2011).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2667">Immunization with DENV-4-DNAv induced significant protection against DENV-4 challenge, where 80% of the challenged mice survived (Lima et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2667">Fifteen days after the third inoculation, the mice were challenged intracerebrally with a dose of 100LD50, prepared from a DENV-4-infected suckling mouse brain. Mouse mortality was monitored daily for 21 days (Lima et al., 2011).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3784">
		<vaccine_name>Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004474</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVR1012 (Vical Inc, San Diego, CA) [Ref2411:Porter et al., 1998]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1526" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1527" gene_id="gene1378">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1211" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2411">In a lethal mouse intracerebral challenge model, the vaccine provided a significant level of protection. Sixty percent of the mice immunized with the DEN DNA vaccine plus pUC 19 survived the challenge compared to only 10% in the control group that received vector plus pUC (Porter et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3781">
		<vaccine_name>Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004472</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref2409:Costa et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1315" gene_id="gene781">
			<type>DNA vaccine construction</type>
			<description refs="reference2409">Vector pcDNA3 expressed the secretory signal sequence derived from human tissue plasminogen activator (t-PA) fused to the full length of the DENV-2 NS1 gene (Costa et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1210" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2409">Vaccinated animals were challenged against DENV-2 in two murine models, based on intracerebral (i.c.) and intraperitoneal (i.p.) virus inoculations, and in both cases, pcTPANS1-immunized mice were protected (Costa et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3779">
		<vaccine_name>Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004471</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcTPA plasmid , a modified pcDNA3 vector (Invitrogen) [Ref2408:Azevedo et al., 2011]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1313" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs="reference2408">Vector pcTPA plasmid , a modified pcDNA3 vector (Invitrogen) expressed amino acids 1â€“398 of the E protein (Azevedo et al., 2011).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1209" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2408">All pE1D2-vaccinated mice survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the pE2D2 showed effects of the disease with high morbidity degrees (Azevedo et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3770">
		<vaccine_name>Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004466</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pMV10.1  [Ref2403:Raviprakash et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1296" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1  expressed prM and E genes in which the N-terminal 90% of E gene was shuffled (Raviprakash et al., 2006).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1297" gene_id="gene1378">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1 expressed prM and E genes in which the N-terminal 90% of E gene was shuffled (Raviprakash et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1204" host_id="host39">
			<immune_response refs="reference2403">Five of six animals vaccinated developed antibodies that neutralized all 4 dengue serotypes in vitro (Raviprakash et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2403">When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3773">
		<vaccine_name>Dengue virus DNA vaccine sABC encoding prM and E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004469</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pMV10.1  [Ref2403:Raviprakash et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1301" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1 expressed premembrane and envelope genes of each of four serotypes of dengue viruses (Raviprakash et al., 2006).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1302" gene_id="gene1378">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1 expressed premembrane and envelope genes of each of four serotypes of dengue viruses (Raviprakash et al., 2006).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1409" gene_id="gene1619">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">This combination vaccine encoded all the proteins from all 3 vaccines (Raviprakash et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1207" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2403">When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed.  The best protection against dengue-1 viremia was demonstrated by the mixture of shuffled vaccines (sABC) out of all the vaccines tested (Raviprakash et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3771">
		<vaccine_name>Dengue virus DNA vaccine sB encoding E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004467</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pMV10.1  [Ref2403:Raviprakash et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1298" gene_id="gene1619">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1 expressed a shuffled truncated E protein (Raviprakash et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1205" host_id="host39">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2403">When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3772">
		<vaccine_name>Dengue virus DNA vaccine sC encoding prM and E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004468</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pMV10.1  [Ref2403:Raviprakash et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1299" gene_id="gene780">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1  expressed prM and E genes in which the N-terminal 90% of E gene was shuffled.a shuffled truncated E protein (Raviprakash et al., 2006).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1300" gene_id="gene1378">
			<type>DNA vaccine construction</type>
			<description refs="reference2403">Vector pMV10.1  expressed prM and E genes in which the N-terminal 90% of E gene was shuffled.a shuffled truncated E protein (Raviprakash et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1206" host_id="host39">
			<immune_response refs="reference2403">Four of six animals vaccinated developed antibodies that neutralized all 4 dengue serotypes in vitro (Raviprakash et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2403">When challenged with live dengue-1 or dengue-2 virus, partial protection against dengue-1 was observed (Raviprakash et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene1619">
        <gene_name>18H6 synthetic E protein</gene_name>
        <strain>synthetic construct</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>73915390</ncbi_nucleotide_id>
        <ncbi_protein_id>73915391</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>AAZ92557.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279241
CDD:280922
CDD:213897</xrefs>
        <taxonomy_id>32630</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>chimeric Dengue envelope antigen 18H6</protein_name>
        <protein_pi>7.33</protein_pi>
        <protein_weight>46583.77</protein_weight>
        <protein_length>549</protein_length>
        <protein_note>derived from Dengue virus</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|73915390|gb|DQ158253.1| Synthetic construct chimeric Dengue envelope antigen 18H6 mRNA, partial cds
ATGGTGGTGATCTTCATCCTGCTGATGCTGGTGACCCCCTCCATGACAATGAGGTGCGTGGGCGTGGGCA
ACAGGGACTTCGTGGAGGGCCTGAGCGGCGCCACCTGGGTGGACGTGGTGCTGGAGCACGGCGGCTGCGT
GACCACCATGGCCAAGAACAAGCCCACCCTGGACTTCGAGCTGATCAAGACCACCGCCAAGGAGGTGGCC
CTGCTGAGGACCTACTGCATCGAGGCCAGCATCAGCAACATCACCACCGCCACCAGGTGCCCCACCCAGG
GCGAGGCCATCCTGCCCGAGGAGCAGGACCAGAACTACGTGTGCAAGCACACCTACGTGGACAGGGGCTG
GGGCAACGGCTGCGGCCTGTTCGGCAAGGGCAGCCTGGTGACCTGCGCCAAGTTCACCTGCAAGAAGAAC
ATGGAGGGCAACATCGTGCAGCCCGAGAACCTGGAGTACACCATCGTGATCACCCCCCACACCGGCGACC
AGCACCAGGTGGGCAACGACACCCAGGGCGTGACCGTGGAGATCACCCCCCAGGCCAGCACCGTGGAGGC
CATCCTGCCCGAGTACGGCACCCTGGGCCTGGAGTGCAGCCCCAGGACTGGCCTGGACTTCAACAGGGTG
GTGCTGCTGACCATGAAGAAGAAGAGCTGGCTGGTGCACAAGCAGTGGTTCCTGGACCTGCCCCTGCCCT
GGACCGCCGGCGCCGACACCAGCGAGGTGCACTGGAACCACAAGGAGAGGATGGTGACCTTCAAGAACGC
CCACGCCAAGAGGCAGGACGTGACCGTGCTGGGCAGCCAGGAGGGCGCCATGCACAGCGCCCTGGCCGGC
GCCACCGAGATCCAGATGAGCAGCGGCAACCTGCTGTTCACCGGCCACCTGAAGTGCAGGCTGAAGATGG
ACAAGCTGCAGCTGAAGGGCGTGAGCTACGTGATGTGCACCGGCAGCTTCAAGCTGGAGAAGGAGGTGGC
CGAGACCCAGCACGGCACCGTGCTGGTGCAGGTGAAGTACGAGGGCACCGACGCCCCCTGCAAGATCCCC
TTCAGCACCGAGGACGGCCAGGGCAAGGCCCACAACGGCAGGCTGATCACCGTGAACCCCATCGTGATCG
ACAAGGAGAAGCCCGTGAACATCGAGCTGGAGCCCCCCTTCGGCGAGAGCTACATCGTGGTGGGCGCCGG
CGAGAAGGCCCTGAAGCTGAGCTGGTTCAAGAAGGGCAGCAGCATCGGCAAGATGTTCGAGGCCACCGCC
AGGGGCGCCAAGAGGATGGCCATCCTGGGCGAGACCGCCTGGGACTTCGGCAGCGTGGGCGGCCTGCTGA
CCAGCCTGGGCAAGGCCGTGCACCAGGTGTTCGGCGCCATCTACGGCGCC</dna_sequence>
        <protein_sequence>>AAZ92557.1 chimeric Dengue envelope antigen 18H6, partial [synthetic construct]
MVVIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATWVDVVLEHGGCVTTMAKNKPTLDFELIKTTAKEVA
LLRTYCIEASISNITTATRCPTQGEAILPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVTCAKFTCKKN
MEGNIVQPENLEYTIVITPHTGDQHQVGNDTQGVTVEITPQASTVEAILPEYGTLGLECSPRTGLDFNRV
VLLTMKKKSWLVHKQWFLDLPLPWTAGADTSEVHWNHKERMVTFKNAHAKRQDVTVLGSQEGAMHSALAG
ATEIQMSSGNLLFTGHLKCRLKMDKLQLKGVSYVMCTGSFKLEKEVAETQHGTVLVQVKYEGTDAPCKIP
FSTEDGQGKAHNGRLITVNPIVIDKEKPVNIELEPPFGESYIVVGAGEKALKLSWFKKGSSIGKMFEATA
RGAKRMAILGETAWDFGSVGGLLTSLGKAVHQVFGAIYGA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1381">
        <gene_name>E</gene_name>
        <strain>Dengue virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>148372385</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279241
CDD:332896
CDD:213392
CDD:213897</xrefs>
        <taxonomy_id>11053</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>7.42</protein_pi>
        <protein_weight>50024.4</protein_weight>
        <protein_length>559</protein_length>
        <protein_note>Flavivirus glycoprotein, central and dimerisation domains; pfam00869</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ABQ63116.1 envelope protein, partial [Dengue virus 1]
MRCVGIGSRDFVEGLSGATWVDVVLEHGSCVTTMAKDKPTLDIELLKTEVTNPAVLRKLCIEAKISNTTT
DSRCPTQGEATLVEEQDANFVCRRTFVDRGWGNGCGLFGKGSLITCAKFKCVTKLEGKIVQYENLKYSVI
VTVHTGDQHQVGNESTEHGTTATITPQAPTTEIQLTDYGALTLDCSPRTGLDFNEMVLLTMKEKSWLVHK
QWFLDLPLPWTSGASTSQETWNRQDLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTTTIFA
GHLKCRLKMDKLTLKGMSYVMCTGSFKLEKEVAETQHGTVLVQIKYEGTDAPCKIPFSTQDEKGVTQNGR
LITANPIVTDKEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARGARRMAILGDTAW
DFGSIGGVFTSVGKLVHQIFGTAYGVLFSGVSWTMKIGIGVLLTWLGLNSRSTSLSMTCIAVGLVTLYLG
VMVQA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1383">
        <gene_name>E</gene_name>
        <strain>Dengue virus 4</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>369726339</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279241
CDD:213392
CDD:213897</xrefs>
        <taxonomy_id>11070</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>7.29</protein_pi>
        <protein_weight>49911.732</protein_weight>
        <protein_length>559</protein_length>
        <protein_note>type: Dengue virus; genotype: IIa</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AEX20298.1 envelope protein, partial [Dengue virus 4]
MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQGKPTLDFELTKTTAKEVALLRTYCIEASISNITT
ATRCPTQGEPYLKEEQDQQYICRRDVVDRGWGNGCGLFGKGGVVTCAKFLCSGKITGNLVQIENLEYTVV
VTVHNGDTHAVGNDTSNHGVTATITPRSPSVEVKLPDYGELTLDCEPRSGIDFNEMILMKMKKKTWLVHK
QWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDVTVLGSQEGAMHSALAGATEVDSGDGNHMFA
GHLKCKVRMEKLRIKGMSYTMCSGKFSIDKEMAETQHGTTVVKVKYEGAGAPCKIPIEIRDVNKEKVVGR
IISSTPFAENTNSVINIELEPPFGDSYIVIGVGDSALTLHWFRKGSSIGKMFESTYRGAKRMAILGETAW
DFGSVGGLFTSLGKAVHQVFGSVYTTMFGGVSWMIRILIGFLVLWIGTNSRNTSMAMTCIAVGGITLFLG
FTVQA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene780">
        <gene_name>E protein</gene_name>
        <strain></strain>
        <vo_id>VO_0011311</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>202078796</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id>1OAN</pdb_id>
        <xrefs>CDD:279241
CDD:213392
CDD:213897</xrefs>
        <taxonomy_id>11060</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>envelope protein</protein_name>
        <protein_pi>7.67</protein_pi>
        <protein_weight>50568.28</protein_weight>
        <protein_length>559</protein_length>
        <protein_note>Flavivirus glycoprotein, central and dimerisation domains; pfam00869</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ACH96447.1 envelope protein, partial [Dengue virus 2]
MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKHPATLRKYCIEAKLTNTTT
ASRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFTCKKNMEGKIVQPENLEYTIV
ITPHSGEENAVGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHR
QWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFT
GHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTIVVRVQYEGDGSPCKIPFEIMDLEKRHVLGR
LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLSWFKKGSSIGQMFETTMRGAKRMAILGDTAW
DFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVVITWIGMNSRSTSLSVSLVLVGVVTLYLG
VMVQA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2EA102) was constructed. Both intracellular and extracellular D2EA102 induced neutralizing antibodies in mice and were thus immunogenic. Sixty eight percent (P &gt; 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge [Ref1371:Delenda et al., 1994].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene785">
        <gene_name>M protein</gene_name>
        <strain></strain>
        <vo_id>VO_0011316</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>73671170</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279358</xrefs>
        <taxonomy_id>11070</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>membrane (M) protein</protein_name>
        <protein_pi>7.7</protein_pi>
        <protein_weight>8254.03</protein_weight>
        <protein_length>129</protein_length>
        <protein_note>Flavivirus envelope glycoprotein M; pfam01004</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>NP_740316.1 membrane (M) protein [Dengue virus 4]
SVALTPHSGMGLETRAETWMSSEGAWKHAQRVESWILRNPGFALLAGFMAYMIGQTGIQRTVFFVLMMLV
APSYG

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A recombinant vaccinia virus that expressed the M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [Ref1376:Bray and Lai, 1991].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene781">
        <gene_name>NS1</gene_name>
        <strain></strain>
        <vo_id>VO_0011312</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>288848</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:213897
CDD:279316
InterPro:IPR001157
UniProtKB/TrEMBL:Q06371</xrefs>
        <taxonomy_id>11060</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>7.2</protein_pi>
        <protein_weight>41028.15</protein_weight>
        <protein_length>429</protein_length>
        <protein_note>flavivirus envelope glycoprotein E, stem/anchor domain; TIGR04240</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAA78918.1 NS1, partial [Dengue virus 2]
MNSRSTSLSVSQVLVGIVTLYLGVMVQADSGCVVSWKNKELKCGSGIFVTDNVHTRTEQYKFQPESPSKL
ASAIQKAHEEGICGIRSVTRLENLMWKQITSELNHILSENEVKLTIMTGDIKGIMQVGKRSLRPQPTELR
YSWKTWGKAKMLSTELHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLRLREKQDAFCDSK
LMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKSCHWPKSHTLWSNGVLESEMVIPKNFAGPKS
QHNNRPGYHTQTAGPWHLGKLEMDFDFCEGTTVVVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLR
YRGEDGCWYGMEIRPLKEKEENLVSSLVTA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The protective efficacy and immune responses of mice intramuscularly injected with plasmid encoding DEN-2 non-structural protein 1 (NS1) was evaluated. Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival [Ref1374:Wu et al., 2003].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene784">
        <gene_name>prM</gene_name>
        <strain></strain>
        <vo_id>VO_0011315</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>18308086</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279856
CDD:279358</xrefs>
        <taxonomy_id>11070</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>premembrane</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>184</protein_length>
        <protein_note>Flavivirus polyprotein propeptide; pfam01570</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAL67829.1 premembrane, partial [Dengue virus 4]
FHLSTRDGEPLMIVAKHERGRPLLFKTTEGINKCTLIAMDLGEMCEDTVTYKCPLLVNTEPEDIDCWCNL
TSTWVMYGTCPQSGERRREKRSVALTPHSGMGLETRAETWMSSEGAWKHAQRVESWILRNP

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A recombinant vaccinia virus that expressed the pre-M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [Ref1376:Bray and Lai, 1991].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1378">
        <gene_name>prM</gene_name>
        <strain>Dengue virus 2</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>18308058</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279856
CDD:279358</xrefs>
        <taxonomy_id>11060</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>premembrane</protein_name>
        <protein_pi>6.34</protein_pi>
        <protein_weight>13464.2</protein_weight>
        <protein_length>172</protein_length>
        <protein_note>Flavivirus polyprotein propeptide; pfam01570</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAL67815.1 premembrane, partial [Dengue virus 2]
FHLTTRNGEPHMIVSRQEKGKSLLFKTKDGTNMCTLMAMDLGELCEDTITYKCPFLKQNEPEDIDCWCNS
TSTWVTYGTCTTTGEHRREKRSVALVPHVGMGLETRTETWMSSEGAWKH

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1380">
        <gene_name>prM</gene_name>
        <strain>Dengue virus 1</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>18308046</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279856
CDD:279358</xrefs>
        <taxonomy_id>11053</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>premembrane</protein_name>
        <protein_pi>5.16</protein_pi>
        <protein_weight>11796.33</protein_weight>
        <protein_length>161</protein_length>
        <protein_note>Flavivirus polyprotein propeptide; pfam01570</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAL67809.1 premembrane, partial [Dengue virus 1]
FHLTTRGGEPHMIVSKQERGKSLLFKTSAGVNMCTLIAMDLGELCEDTMTYKCPRITEAEPDDVDCWCNA
TDTWVTYGTCSQTGEHRRDKRSVALAPHVGLGLETRTE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference2408">
		<reference_name>Azevedo et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Azevedo AS, Yamamura AM, Freire MS, Trindade GF, Bonaldo M, Galler R, Alves AM</authors>
		<title>DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III</title>
		<year>2011</year>
		<volume>6</volume>
		<issue>7</issue>
		<pages>e20528</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1376">
		<reference_name>Bray and Lai, 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bray M, Lai CJ</authors>
		<title>Dengue virus premembrane and membrane proteins elicit a protective immune response</title>
		<year>1991</year>
		<volume>185</volume>
		<issue>1</issue>
		<pages>505-508</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2668">
		<reference_name>Chen et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, Sedegah M, Hayes C, Porter K, Raviprakash K</authors>
		<title>A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques</title>
		<year>2007</year>
		<volume>81</volume>
		<issue>21</issue>
		<pages>11634-11639</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2409">
		<reference_name>Costa et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Costa SM, Paes MV, Barreto DF, PinhÃƒÂ£o AT, Barth OM, Queiroz JL, ArmÃƒÂ´a GR, Freire MS, Alves AM</authors>
		<title>Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>2</issue>
		<pages>195-205</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1371">
		<reference_name>Delenda et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Delenda C, Frenkiel MP, Deubel V</authors>
		<title>Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells</title>
		<year>1994</year>
		<volume>139</volume>
		<issue>1-2</issue>
		<pages>197-207</pages>
		<journal_book_name>Archives of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2406">
		<reference_name>Konishi et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Konishi E, Yamaoka M, Kurane I, Mason PW</authors>
		<title>A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice</title>
		<year>2000</year>
		<volume>18</volume>
		<issue>11-12</issue>
		<pages>1133-1139</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2405">
		<reference_name>Konishi et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Konishi E, Terazawa A, Fujii A</authors>
		<title>Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>25-26</issue>
		<pages>3713-3720</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2404">
		<reference_name>Konishi et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Konishi E, Kosugi S, Imoto J</authors>
		<title>Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>12</issue>
		<pages>2200-2207</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2667">
		<reference_name>Lima et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lima DM, de Paula SO, FranÃƒÂ§a RF, Palma PV, Morais FR, Gomes-Ruiz AC, de Aquino MT, da Fonseca BA</authors>
		<title>A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>4</issue>
		<pages>831-838</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1373">
		<reference_name>Liu et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liu WT, Lin WT, Tsai CC, Chuang CC, Liao CL, Lin HC, Hung YW, Huang SS, Liang CC, Hsu HL, Wang HJ, Liu YT</authors>
		<title>Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>31-32</issue>
		<pages>5852-5861</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1550">
		<reference_name>Martina et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Martina BE, Koraka P, Osterhaus AD</authors>
		<title>Dengue virus pathogenesis: an integrated view</title>
		<year>2009</year>
		<volume>22</volume>
		<issue>4</issue>
		<pages>564-581</pages>
		<journal_book_name>Clinical microbiology reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2411">
		<reference_name>Porter et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG</authors>
		<title>Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses</title>
		<year>1998</year>
		<volume>143</volume>
		<issue>5</issue>
		<pages>997-991003</pages>
		<journal_book_name>Archives of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2402">
		<reference_name>Ramanathan et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ramanathan MP, Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, Weiner DB</authors>
		<title>Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes</title>
		<year>2009</year>
		<volume>27</volume>
		<issue>46</issue>
		<pages>6444-6453</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2407">
		<reference_name>Raviprakash et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG</authors>
		<title>Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques</title>
		<year>2000</year>
		<volume>81</volume>
		<issue>Pt 7</issue>
		<pages>1659-1667</pages>
		<journal_book_name>The Journal of general virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2410">
		<reference_name>Raviprakash et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS</authors>
		<title>Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF</title>
		<year>2001</year>
		<volume>290</volume>
		<issue>1</issue>
		<pages>74-82</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2403">
		<reference_name>Raviprakash et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, Porter K</authors>
		<title>A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques</title>
		<year>2006</year>
		<volume>353</volume>
		<issue>1</issue>
		<pages>166-173</pages>
		<journal_book_name>Virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3100">
		<reference_name>Raviprakash et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K</authors>
		<title>A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus</title>
		<year>2008</year>
		<volume>82</volume>
		<issue>14</issue>
		<pages>6927-6934</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1374">
		<reference_name>Wu et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK</authors>
		<title>Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>25-26</issue>
		<pages>3919-3929</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


